Trial intelligence / Profile preview

Atomoxetine for Work Productivity in Adult ADHD

NCT00190931Phase 4Completed

Sponsor
Eli Lilly and Company
Start
Nov 2003
Modality
Small Molecules
Countries
1
01

Overview

A Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Nov 2003; status: completed.

02

Drugs

atomoxetine
03

Conditions

attention deficit hyperactivity disorder (ADHD)

Beyond the preview

Go deeper on NCT00190931.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00190931.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call